Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics shares declined after the company's Phase 2a study of SPR720 failed to meet its primary endpoint.
October 29, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Spero Therapeutics' stock is trading lower due to the failure of its Phase 2a study of SPR720 to meet the primary endpoint.
The failure of the Phase 2a study to meet its primary endpoint is a significant setback for Spero Therapeutics, likely leading to a negative short-term impact on the stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100